← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Purine analogues
fludarabine
L01BB05
Forms & Strengths
- Injection: 50mg/mL
- Tablet: 10mg
Adult Dosing
- Induction: 25-30 mg/m² IV daily for 5 days
- Maintenance: 20-30 mg/m² IV daily for 5 days every 4 weeks
Pediatric Dosing
- Not established for patients under 18 years
- May use in clinical trials with close monitoring
Indications
- Chronic lymphocytic leukemia (CLL)
- Acute myeloid leukemia (AML)
- Non-Hodgkin lymphoma (NHL)
- Cutaneous T-cell lymphoma (CTCL)
Mechanism of Action
- Inhibits DNA polymerase and ribonucleotide reductase
- Interferes with DNA synthesis and repair
- Induces apoptosis in cancer cells
Contraindications
- Pregnancy and lactation
- Hypersensitivity to fludarabine
- Severe bone marrow suppression
Adverse Reactions
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Infection
- Neurotoxicity
Drug Interactions
- Enhanced toxicity with pentostatin
- Increased risk of bleeding with anticoagulants
- Reduced efficacy with live vaccines
Curated Content: Needs Vetting Before Put to Clinical Use